Selective COX-2 inhibitors are also associated with a decline in the incidence of CRC and reduced mortality rate, although COX-2 inhibitors have been associated with serious cardiovascular events in this context [10]. This evidence concerns the gene PTGS2 and colorectal carcinoma.